A Phase II Study Evaluating RNS60 Compared to Interferon Beta-1a (Avonex) for the Treatment of Relapsing Remitting Multiple Sclerosis
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2016
At a glance
- Drugs RNS 60 (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Revalesio
- 05 Apr 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 30 Jan 2014 Planned End Date changed from 1 Feb 2016 to 1 Oct 2016 as reported by ClinicalTrials.gov.
- 05 Sep 2013 Planned End Date changed from 1 Sep 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov.